Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,779
datasets available to search
ShareScore release 0.9.0
Dataset results
1,779 results for “Hodgkin lymphoma”
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00417014. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
ClinicalTrials.gov study NCT00416377. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dynamic Quantitative Analytic Response of Human Natural Killer Cells at Single-Cell Resolution in B-cell Non-Hodgkin Lymphoma
GEO Series GSE102930. Homo sapiens. 21 samples. Type: Expression profiling by array.
CD19 Chimeric Antigen Receptor Engineered NK92 Natural Killer Cells: Novel “Off the Shelf” Immunotherapy in Non-Hodgkin Lymphoma II
GEO Series GSE120316. Homo sapiens. 24 samples. Type: Expression profiling by array.
Gene expression profiling of HIV and EBV-associated classic Hodgkin lymphomas from Malawi
GEO Series GSE289903. Homo sapiens. 19 samples. Type: Expression profiling by high throughput sequencing.
Therapeutic targets and microenvironment in sequential biopsies of classical Hodgkin lymphoma at diagnosis and relapse
GEO Series GSE125651. Homo sapiens. 26 samples. Type: Other.
RNA sequencing of bone marrow macrophages from non-Hodgkin lymphoma Raji cell engrafted mice
GEO Series GSE190598. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
GEO Series GSE178922. Homo sapiens. 28 samples. Type: Expression profiling by high throughput sequencing.
EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma
GEO Series GSE70703. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Gene expression profiling of Hodgkin Lymphoma cell line following REL-B depletion
GEO Series GSE35224. Homo sapiens. 16 samples. Type: Expression profiling by array.
Complex immune evasion strategies in classical Hodgkin lymphoma
GEO Series GSE102693. Homo sapiens. 19 samples. Type: Expression profiling by array.
Single case sample of a Non-Hodgkin lymphoma
GEO Series GSE46005. Homo sapiens. 1 samples. Type: Genome variation profiling by SNP array.
EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma [ChIP-seq]
GEO Series GSE70702. Homo sapiens. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Hodgkin Lymphoma Data Collaboration (NODAL)
Researchers have created this consortium with the goal of establishing a database containing information from clinical trials to enable scientific investigations, including to harmonize staging and response assessment, improve prognostic factors, enable assessment of short and long term toxicity, and study rare subtypes. NODAL will launch a radiation and imaging work group to identify the data available to aid in studies and a Young Adults work group to serve as liaison to the adult trials.
Dataset related to article "Outcome of high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma after different numbers of salvage regimens"
<p>This record contains raw data related to article "Outcome of high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma after different numbers of salvage regimens"</p> <p><strong>Abstract</strong></p> <div> <p>The introduction of novel drugs (<em>PD-1</em> inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so far. We retrospectively analyzed 42 consecutive patients treated at our institution with high-dose chemotherapy/autologous stem cell transplantation after either one standard chemotherapy represented by BEGEV (<em>n</em> = 28) or >1 salvage therapy (ST) comprising novel drugs (<em>n</em> = 14). With a median follow-up of 24 months, the 2-year cumulative incidence of relapse was similar between the two cohorts: 26% for 1 ST and 18% for >1 ST (<em>p</em> = 0.822). Consistently, overall survival and progression-free survival did not differ among the two groups: 3-year overall survival was 91% and 89% (<em>p</em> = 0.731), respectively, and 3-year progression-free survival was 74% and 83% (<em>p</em> = 0.822) for only one and more than one salvage regimens, respectively. Of note, the post-transplant side effects and engraftment rates were similar between the 1 ST and >1 ST cohorts. In conclusion, consolidation with high-dose chemotherapy/autologous stem cell transplantation is a safe and curative option, even for patients achieving disease response after more than one rescue line of therapy.</p> </div>
Dataset related to article "Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"
<p><br> This record contains raw data related to article “Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"</p> <p>We investigated the feasibility and activity of an intensifed dose-dense ABVD (dd-ABVD) regimen in patients with earlystage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients with newly diagnosed, unfavorable stage I or II classical HL. The patients received four cycles of dd-ABVD followed by radiotherapy. Interim PET (PET-2) was mandatory after two courses. Primary endpoints were the evaluation of dd-ABVD feasibility and activity (incidence of PET-2 negativity). The feasibility endpoint was achieved with 48/52 (92.3%) patients receiving>85% of the programmed dose. The mean dose intensity in the overall patient population (n=96) was 93.7%, and the median duration of dd-ABVD was 85 days (range, 14–115) versus an expected duration of 84 days. PET-2 was available for 92/96 (95.8%) patients, of whom 79 were PET-2 negative (85.9%). In total, 90 (93.8%) patients showed complete response at the end of treatment. With a follow-up of 80.9 months (3.3–103.2), the median progression-free survival (PFS) and overall survival (OS) were not reached. At 84 months, PFS and OS rates were 88.4% and 95.7%, respectively. No evidence for a diference in PFS or OS was observed for PET-2-negative and PET-2-positive patients. Infections were documented in 8.3% and febrile neutropenia in 6.2% of cases. Four patients died: one had alveolitis at cycle 3, one death was unrelated to treatment, and two died from a secondary cancer. dd-ABVD is feasible and demonstrates activity in early-stage unfavorable HL. The predictive role of PET-2 positivity in early-stage unfavorable HL remains controversial. The study was registered in the EudraCT (reference number, 2011–003,191-36) and the ClinicalTrials.gov (reference number, NCT02247869) databases.</p>
Dataset related to article "Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics"
<p>This record contains raw data related to article "Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics"</p> <p>Checkpoint inhibitors (CPIs) are routinely employed in relapsed/refractory classical Hodgkin lymphoma. Nonetheless, persistent long-term responses are uncommon, and one-third of patients are refractory. Several reports have suggested that treatment with CPIs may re-sensitize patients to chemotherapy, however there is no consensus on the optimal chemotherapy regimen and subsequent consolidation strategy. In this retrospective study we analysed the response to rechallenge with chemotherapy after CPI failure. Furthermore, we exploratively characterized the clonal evolution profile of a small sample of patients (n = 5) by employing the CALDER approach. Among the 28 patients included in the study, 17 (71%) were primary refractory and 26 (92%) were refractory to the last chemotherapy prior to CPIs. Following rechallenge with chemotherapy, response was recorded in 23 (82%) patients experiencing complete remission and 3 (11%) patients experiencing partial remission. The tumour evolution of the patients inferred by CALDER seemingly occurred prior to the first cycle of therapy and was characterized either by linear or branching evolution patterns.Twenty-five patients proceeded to allogeneic stem cell transplantation. At a median follow-up of 21 months, median PFS and OS were not reached. In conclusion, patients who fail CPIs can be effectively rescued by salvage chemotherapy and bridged to allo-SCT/ auto-SCT.</p>
Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
GEO Series GSE86845. Homo sapiens. 4 samples. Type: Expression profiling by array.
Leukotriene D4 induces early genes in Hodgkin lymphoma cells through Cysteinyl leukotriene type I receptor
GEO Series GSE43855. Homo sapiens. 6 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.